Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2016
Price :
$35
*
At a glance
- Drugs Velafermin (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Sponsors CuraGen Corporation
- 17 Mar 2016 New trial record
- 17 Mar 2016 New trial record